Home › Companies › Viridian Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Viridian Therapeutics, Inc.’s Form 8-K, filed June 3, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 2, 2026: 4 items on Viridian Therapeutics, Inc.’s Form 8-K, filed June 3, 2026: 2 elected · 2 passed (calculated).
Notable dissent: 1 director (16.7% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Caligan Partners (13F, 1.9%, as of September 30, 2026) · Tang Capital (13F, 1.6%, as of September 30, 2026)
Explore Viridian Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Viridian Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Tomas Kiselak | 72,363,500 | -- | -- | 14,475,646 | 6,733,104 | 83% | Elected | — |
| Elect Director: Jennifer K. Moses | 86,378,842 | -- | -- | 460,304 | 6,733,104 | 99.5% | Elected | — |
| 2. Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 92,866,008 | 512,582 | 193,660 | -- | -- | 99.5% | Passed (calculated) | — |
| 3. Approval, on an advisory basis, of the compensation of the Company's named executive officers | 83,512,086 | 3,113,724 | 213,336 | -- | 6,733,104 | 96% | Passed (calculated) | — |
Source: Viridian Therapeutics, Inc., Form 8-K, filed with the SEC on June 3, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
238 asset managers disclosed a vote on at least one Viridian Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Viridian Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Jennifer K. Moses
Viridian Therapeutics, Inc.’s own tally for this item (“Elect Director: Jennifer K. Moses”): 86,378,842 for, 460,304 withheld, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 36,614,137 for, 38,566 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,739,881 | 0 | 0 | 0 | For |
| Vanguard | 5,760,697 | 0 | 1 | 3,349 | For |
| BlackRock | 3,585,861 | 0 | 0 | 0 | For |
| State Street | 2,984,281 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,198,781 | 0 | 0 | 0 | For |
| Charles Schwab | 728,176 | 0 | 0 | 0 | For |
| AllianceBernstein | 699,197 | 0 | 0 | 0 | For |
| TIAA | 537,564 | 0 | 0 | 0 | For |
| Hartford | 535,695 | 0 | 0 | 0 | For |
| Federated Hermes | 437,409 | 0 | 0 | 0 | For |
| Victory Capital | 349,635 | 0 | 0 | 0 | For |
| First Trust | 301,086 | 0 | 0 | 0 | For |
| Voya | 228,925 | 0 | 0 | 0 | For |
| Equitable | 189,013 | 0 | 0 | 0 | For |
| SEI | 170,597 | 0 | 0 | 0 | For |
| Dimensional | 166,453 | 0 | 0 | 0 | For |
| Principal | 160,413 | 0 | 0 | 0 | For |
| Goldman Sachs | 152,584 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 148,838 | 0 | 0 | 0 | For |
| Brighthouse | 124,083 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 117,276 | 0 | 0 | 0 | For |
| Northwestern Mutual | 111,485 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 100,977 | 0 | 0 | 0 | For |
| JPMorgan | 98,935 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 93,301 | 0 | 0 | 0 | For |
Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Tomas Kiselak
Viridian Therapeutics, Inc.’s own tally for this item (“Elect Director: Tomas Kiselak”): 72,363,500 for, 14,475,646 withheld, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 30,829,621 for, 5,823,066 withheld, 17 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,739,881 | 0 | 0 | 0 | For |
| Vanguard | 5,760,681 | 0 | 17 | 3,349 | For |
| BlackRock | 3,585,861 | 0 | 0 | 0 | For |
| State Street | 8,799 | 0 | 0 | 2,975,482 | Withhold |
| T. Rowe Price | 2,198,781 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 728,176 | Withhold |
| AllianceBernstein | 699,197 | 0 | 0 | 0 | For |
| TIAA | 537,564 | 0 | 0 | 0 | For |
| Hartford | 0 | 0 | 0 | 535,695 | Withhold |
| Federated Hermes | 0 | 0 | 0 | 437,409 | Withhold |
| Victory Capital | 345,923 | 0 | 0 | 3,712 | For |
| First Trust | 301,086 | 0 | 0 | 0 | For |
| Voya | 228,925 | 0 | 0 | 0 | For |
| Equitable | 189,013 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 0 | 170,597 | Withhold |
| Dimensional | 0 | 0 | 0 | 166,453 | Withhold |
| Principal | 160,413 | 0 | 0 | 0 | For |
| Goldman Sachs | 142,628 | 0 | 0 | 9,956 | Mixed |
| Bridge Builder Trust | 19,740 | 0 | 0 | 129,098 | Mixed |
| Brighthouse | 124,083 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 117,276 | 0 | 0 | 0 | For |
| Northwestern Mutual | 0 | 0 | 0 | 111,485 | Withhold |
| CLEARWATER INVESTMENT TRUST | 0 | 0 | 0 | 100,977 | Withhold |
| JPMorgan | 98,935 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 93,301 | 0 | 0 | 0 | For |
Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 77.8% for (June 20, 2025 meeting) ▲ 18.6 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.
Viridian Therapeutics, Inc.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers”): 83,512,086 for, 3,113,724 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,739,881 | 0 | 0 | 0 | For |
| Vanguard | 5,760,693 | 3,354 | 0 | 0 | For |
| BlackRock | 3,585,861 | 0 | 0 | 0 | For |
| State Street | 2,983,189 | 1,092 | 0 | 0 | For |
| T. Rowe Price | 2,198,781 | 0 | 0 | 0 | For |
| Charles Schwab | 728,176 | 0 | 0 | 0 | For |
| AllianceBernstein | 699,197 | 0 | 0 | 0 | For |
| TIAA | 537,564 | 0 | 0 | 0 | For |
| Hartford | 535,695 | 0 | 0 | 0 | For |
| Federated Hermes | 437,409 | 0 | 0 | 0 | For |
| Victory Capital | 349,635 | 0 | 0 | 0 | For |
| First Trust | 301,086 | 0 | 0 | 0 | For |
| Voya | 228,925 | 0 | 0 | 0 | For |
| Equitable | 189,013 | 0 | 0 | 0 | For |
| SEI | 170,597 | 0 | 0 | 0 | For |
| Dimensional | 166,453 | 0 | 0 | 0 | For |
| Principal | 160,413 | 0 | 0 | 0 | For |
| Goldman Sachs | 152,584 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 148,838 | 0 | 0 | 0 | For |
| Brighthouse | 124,083 | 0 | 0 | 0 | For |
| Northwestern Mutual | 111,485 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 100,977 | 0 | 0 | 0 | For |
| JPMorgan | 98,935 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 93,301 | 0 | 0 | 0 | For |
| Russell Investments | 82,177 | 0 | 0 | 0 | For |
Fund voting reports, all 64 managers: 36,487,409 for, 5,677 against, 35,217 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 14,697,644 | 0 | 0 | 0 | For |
| State Street | 4,638,954 | 2,123 | 0 | 0 | For |
| Fairmount Funds Management LLC | 3,914,458 | 0 | 0 | 0 | For |
| Venrock Adviser, LLC | 3,760,028 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,350,531 | 0 | 0 | 0 | For |
| BlackRock | 3,033,331 | 10,929 | 0 | 0 | For |
| Wellington | 2,500,152 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,338,151 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 2,000,000 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,892,281 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 1,662,358 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,315,542 | 0 | 0 | 0 | For |
| Citadel | 1,060,278 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 697,319 | 250,419 | 0 | 0 | Mixed |
| DE Shaw | 822,573 | 0 | 0 | 0 | For |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,848 | 0 | 0 | 0 | For |
| Charles Schwab | 738,309 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 711,739 | 0 | 0 | Against |
| Eversept Partners, LP | 693,251 | 0 | 0 | 0 | For |
| Vanguard | 687,608 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 686,669 | 0 | 0 | 0 | For |
| Federated Hermes | 656,433 | 4,970 | 0 | 0 | For |
| MPM BioImpact LLC | 612,763 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 598,965 | 0 | 0 | 0 | For |
| Northern Trust | 551,397 | 5,721 | 0 | 0 | For |
Institutional-manager reports, all 194 managers: 59,520,359 for, 2,141,349 against, 99 abstained, 18,613 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| Hartford | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| First Trust | 0 | 0 | 0 | 0 | -- |
| Voya | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| SEI | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| Principal | 0 | 0 | 0 | 0 | -- |
| Goldman Sachs | 0 | 0 | 0 | 0 | -- |
| Bridge Builder Trust | 0 | 0 | 0 | 0 | -- |
| Brighthouse | 124,083 | 0 | 0 | 0 | For |
| Northwestern Mutual | 0 | 0 | 0 | 0 | -- |
| CLEARWATER INVESTMENT TRUST | 0 | 0 | 0 | 0 | -- |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 0 | -- |
| Russell Investments | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 64 managers: 124,083 for, 35,217 abstained, 36,190,378 1 year, 178,489 3 year, 135 unknown. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Fairmount Funds Management LLC | 0 | 0 | 0 | 0 | -- |
| Venrock Adviser, LLC | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Wellington | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Novo Holdings A/S | 0 | 0 | 0 | 0 | -- |
| Deep Track Capital, LP | 0 | 0 | 0 | 0 | -- |
| Paradigm Biocapital Advisors LP | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| Fisher Asset Management, LLC | 0 | 0 | 0 | 0 | -- |
| DE Shaw | 0 | 0 | 0 | 0 | -- |
| RICE HALL JAMES & ASSOCIATES, LLC | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Candriam S.C.A. | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| PERCEPTIVE ADVISORS LLC | 686,669 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| MPM BioImpact LLC | 0 | 0 | 0 | 0 | -- |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Nuveen | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 188 managers: 752,848 for, 344 against, 59,918,530 1 year, 85,828 3 year, 8,194 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Prior year: 99.2% for (June 20, 2025 meeting) ▲ 0.2 pts
Description as filed by funds: TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.
Viridian Therapeutics, Inc.’s own tally for this item (“2. Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 92,866,008 for, 512,582 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 36,617,368 for, 119 against, 35,217 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,739,881 | 0 | 0 | 0 | For |
| Vanguard | 5,764,046 | 1 | 0 | 0 | For |
| BlackRock | 3,585,861 | 0 | 0 | 0 | For |
| State Street | 2,984,163 | 118 | 0 | 0 | For |
| T. Rowe Price | 2,198,781 | 0 | 0 | 0 | For |
| Charles Schwab | 728,176 | 0 | 0 | 0 | For |
| AllianceBernstein | 699,197 | 0 | 0 | 0 | For |
| TIAA | 537,564 | 0 | 0 | 0 | For |
| Hartford | 535,695 | 0 | 0 | 0 | For |
| Federated Hermes | 437,409 | 0 | 0 | 0 | For |
| Victory Capital | 349,635 | 0 | 0 | 0 | For |
| First Trust | 301,086 | 0 | 0 | 0 | For |
| Voya | 228,925 | 0 | 0 | 0 | For |
| Equitable | 189,013 | 0 | 0 | 0 | For |
| SEI | 170,597 | 0 | 0 | 0 | For |
| Dimensional | 166,453 | 0 | 0 | 0 | For |
| Principal | 160,413 | 0 | 0 | 0 | For |
| Goldman Sachs | 152,584 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 148,838 | 0 | 0 | 0 | For |
| Brighthouse | 124,083 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 117,276 | 0 | 0 | 0 | For |
| Northwestern Mutual | 111,485 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 100,977 | 0 | 0 | 0 | For |
| JPMorgan | 98,935 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 93,301 | 0 | 0 | 0 | For |
Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 103,074,740 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 15.27% |
| 2 | Vanguard | 5.59% |
| 3 | BlackRock | 3.48% |
| 4 | State Street | 2.90% |
| 5 | T. Rowe Price | 2.13% |
| 6 | Charles Schwab | 0.71% |
| 7 | AllianceBernstein | 0.68% |
| 8 | TIAA | 0.52% |
| 9 | Hartford | 0.52% |
| 10 | Federated Hermes | 0.42% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.26% |
| 2 | State Street | 4.50% |
| 3 | Fairmount Funds Management LLC | 3.80% |
| 4 | Venrock Adviser, LLC | 3.65% |
| 5 | T. Rowe Price | 3.25% |
| 6 | BlackRock | 2.95% |
| 7 | Wellington | 2.43% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.27% |
| 9 | Novo Holdings A/S | 1.94% |
| 10 | Deep Track Capital, LP | 1.84% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Fairmount Funds Management LLC | 17,201,800 | 16.69% | Schedule 13D, filed May 13, 2026 |
| Entities affiliated with Fairmount Funds Management LLC | 16,025,330 | 15.55% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| Entities affiliated with FMR LLC | 7,625,542 | 7.40% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| Bellevue Group AG | 6,726,144 | 6.53% | Schedule 13G, filed May 15, 2026 |
| Paradigm BioCapital Advisors LP | 6,723,788 | 6.52% | Schedule 13G, filed August 14, 2026 |
| STATE STREET CORPORATION | 6,124,976 | 5.94% | Schedule 13G, filed August 7, 2026 |
| T. Rowe Price Associates, Inc. | 5,748,426 | 5.58% | Schedule 13G, filed August 14, 2026 |
| Point72 Asset Management, L.P. | 5,687,507 | 5.52% | Schedule 13G, filed August 20, 2026 |
| Deep Track Capital, LP | 3,592,740 | 3.49% | Schedule 13G, filed August 14, 2026 |
| Stephen Mahoney | 1,016,882 | 0.99% | Proxy statement (DEF 14A), table as of March 31, 2026 |
Percentages above are of 103,074,740 shares outstanding, as reported by Viridian Therapeutics, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Viridian Therapeutics, Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 238 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,899 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Viridian Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Viridian Therapeutics, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Viridian Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Viridian Therapeutics (VRDN) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/viridian-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.